SG10201802789VA - Use of a vegf antagonist to treat angiogenic eye disorders - Google Patents

Use of a vegf antagonist to treat angiogenic eye disorders

Info

Publication number
SG10201802789VA
SG10201802789VA SG10201802789VA SG10201802789VA SG10201802789VA SG 10201802789V A SG10201802789V A SG 10201802789VA SG 10201802789V A SG10201802789V A SG 10201802789VA SG 10201802789V A SG10201802789V A SG 10201802789VA SG 10201802789V A SG10201802789V A SG 10201802789VA
Authority
SG
Singapore
Prior art keywords
vegf antagonist
eye disorders
angiogenic eye
treat angiogenic
treat
Prior art date
Application number
SG10201802789VA
Other languages
English (en)
Inventor
D Yancopoulos George
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45507924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201802789V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201802789VA publication Critical patent/SG10201802789VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG10201802789VA 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders SG10201802789VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161432245P 2011-01-13 2011-01-13
US201161434836P 2011-01-21 2011-01-21
US201161561957P 2011-11-21 2011-11-21

Publications (1)

Publication Number Publication Date
SG10201802789VA true SG10201802789VA (en) 2018-05-30

Family

ID=45507924

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201509193UA SG10201509193UA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG2013048798A SG191334A1 (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG10202111177VA SG10202111177VA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG10201802789VA SG10201802789VA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SG10201509193UA SG10201509193UA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG2013048798A SG191334A1 (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG10202111177VA SG10202111177VA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders

Country Status (13)

Country Link
US (13) US9254338B2 (zh)
EP (4) EP4360709A3 (zh)
JP (5) JP2014503555A (zh)
KR (7) KR20180023015A (zh)
CN (1) CN103533950A (zh)
AU (5) AU2012205599B2 (zh)
BR (1) BR112013017752A8 (zh)
CA (1) CA2824422A1 (zh)
HK (1) HK1244693A1 (zh)
IL (3) IL295359A (zh)
MX (2) MX349901B (zh)
SG (4) SG10201509193UA (zh)
WO (1) WO2012097019A1 (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
CA2824422A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
PT3230316T (pt) * 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
CA2977738A1 (en) * 2015-02-26 2016-09-01 Feramda Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
WO2017046140A1 (en) * 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
EP3380194B1 (en) 2015-11-24 2023-11-01 Indiana University Research & Technology Corporation Composition for blocking angiogenesis
CN108474039B (zh) 2015-12-03 2022-06-07 雷杰纳荣制药公司 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
US11400080B2 (en) 2016-05-25 2022-08-02 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
US11135266B2 (en) 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
EP3573641A4 (en) * 2017-01-25 2020-11-11 Iconic Therapeutics, Inc. TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION
EP3710055A4 (en) * 2017-11-16 2021-07-21 IVERIC bio, Inc. METHOD OF TREATMENT OR PREVENTION OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPV)
SG11202004268PA (en) * 2017-11-30 2020-06-29 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
WO2019154776A1 (en) * 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019175727A1 (en) * 2018-03-16 2019-09-19 Novartis Ag Methods for treating ocular diseases
CA3099551A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US20220143137A1 (en) 2019-02-13 2022-05-12 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
WO2020241660A1 (ja) 2019-05-28 2020-12-03 学校法人順天堂 糖尿病網膜症の予防又は治療薬
EP4028129A2 (en) * 2019-09-12 2022-07-20 Lupin Limited Modified dosing of vegf inhibitors for ophthalmic use
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023502501A (ja) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼内血管新生のための長時間作用型ｖｅｇｆ阻害剤
EP4069264A1 (en) 2019-12-06 2022-10-12 Regeneron Pharmaceuticals, Inc. Vegf mini-traps and methods of use thereof
IL302538A (en) 2019-12-06 2023-07-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
KR102426802B1 (ko) * 2019-12-23 2022-07-28 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
WO2021252647A1 (en) * 2020-06-11 2021-12-16 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
JPWO2022186335A1 (zh) * 2021-03-03 2022-09-09
WO2022221395A1 (en) * 2021-04-14 2022-10-20 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2023013554A (es) * 2021-05-17 2023-11-29 Regeneron Pharma Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos.

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2275119T1 (sl) 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
MEP3208A (xx) 1999-06-08 2010-02-10 Regeneron Pharma Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
RS35404A (en) 2001-11-09 2006-10-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
JP2003309411A (ja) 2002-04-17 2003-10-31 Alps Electric Co Ltd 複合アンテナ
US7300563B2 (en) 2003-02-07 2007-11-27 Pavco, Inc. Use of N-alllyl substituted amines and their salts as brightening agents in nickel plating baths
US7052691B2 (en) 2003-03-28 2006-05-30 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking VEGF-mediated activity
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
WO2004103159A2 (en) 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
WO2004106378A2 (en) 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
EP1732947B1 (en) 2004-03-05 2011-04-27 Vegenics Pty Ltd Growth factor binding constructs materials and methods
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
US7750138B2 (en) 2004-06-08 2010-07-06 Chengdu Kanghong Biotechnologies Co. Ltd. Angiogenesis-inhibiting chimeric protein and the use
CN101102786A (zh) 2004-06-10 2008-01-09 瑞泽恩制药公司 施用并利用vegf抑制剂治疗人类癌症的方法
EP1755645A2 (en) 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
EP2311433A3 (en) 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
PT2586459T (pt) 2005-03-25 2017-07-25 Regeneron Pharma Formulações antagonistas de fcev
WO2007022101A2 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
EP3753548A1 (en) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
AU2007323925A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CA2824422A1 (en) * 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CN107115294B (zh) 2012-01-19 2019-10-18 北京康弘生物医药有限公司 一种含有vegf拮抗剂的滴眼液
UA117045C2 (uk) 2014-01-25 2018-06-11 Ченгду Кангхонг Байотекнолоджиз Ко., Лтд. Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
SG11202004268PA (en) 2017-11-30 2020-06-29 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders

Also Published As

Publication number Publication date
JP2021193115A (ja) 2021-12-23
KR20180023015A (ko) 2018-03-06
KR20220097542A (ko) 2022-07-07
US9254338B2 (en) 2016-02-09
KR20210030510A (ko) 2021-03-17
US20210085753A1 (en) 2021-03-25
IL295359A (en) 2022-10-01
MX349901B (es) 2017-08-18
EP3763379A1 (en) 2021-01-13
US20220273764A1 (en) 2022-09-01
KR20190049934A (ko) 2019-05-09
AU2012205599B2 (en) 2016-10-20
HK1244693A1 (zh) 2018-08-17
EP4360709A3 (en) 2024-07-03
US20170202911A1 (en) 2017-07-20
AU2017200290B2 (en) 2019-01-03
US20210121524A1 (en) 2021-04-29
EP2663325A1 (en) 2013-11-20
US20210308216A1 (en) 2021-10-07
AU2012205599A1 (en) 2013-07-18
US10130681B2 (en) 2018-11-20
BR112013017752A8 (pt) 2018-01-09
SG10202111177VA (en) 2021-11-29
AU2019202260A1 (en) 2019-04-18
SG10201509193UA (en) 2015-12-30
US20130295094A1 (en) 2013-11-07
US11730794B2 (en) 2023-08-22
MX2013007847A (es) 2013-07-29
AU2017200290A1 (en) 2017-02-02
AU2024204677A1 (en) 2024-07-25
JP2014503555A (ja) 2014-02-13
SG191334A1 (en) 2013-08-30
US20160101152A1 (en) 2016-04-14
CA2824422A1 (en) 2012-07-19
KR20240110092A (ko) 2024-07-12
US10828345B2 (en) 2020-11-10
US20240123030A1 (en) 2024-04-18
IL260167A (en) 2018-07-31
EP4360709A2 (en) 2024-05-01
BR112013017752A2 (pt) 2017-08-29
EP3222285A1 (en) 2017-09-27
AU2021200935A1 (en) 2021-03-11
IL227160B (en) 2019-02-28
US11707506B2 (en) 2023-07-25
WO2012097019A1 (en) 2012-07-19
US11986511B2 (en) 2024-05-21
KR20140043313A (ko) 2014-04-09
KR20200077622A (ko) 2020-06-30
US20190247463A1 (en) 2019-08-15
CN103533950A (zh) 2014-01-22
US11975045B2 (en) 2024-05-07
MX2021006092A (es) 2022-05-18
US20190046609A1 (en) 2019-02-14
US10888601B2 (en) 2021-01-12
US20210308217A1 (en) 2021-10-07
US9669069B2 (en) 2017-06-06
US10857205B2 (en) 2020-12-08
JP2024001190A (ja) 2024-01-09
NZ612593A (en) 2015-03-27
US20180339018A1 (en) 2018-11-29
US11559564B2 (en) 2023-01-24
JP2017061467A (ja) 2017-03-30
US20210023173A1 (en) 2021-01-28
US11253572B2 (en) 2022-02-22
JP2019167366A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
IL260167A (en) For the treatment of vegf disorders - use of an agonist for angiogenic eyes
HK1254720A1 (zh) 眼科治療
HK1215375A1 (zh) 阿克曼氏菌用於治療代謝病症的用途
IL274711A (en) Use of a vegf antagonist to treat angiogenic eye disorders
IL233467B (en) Methods for determining whether a patient is likely to respond to treatment with a vegf antagonist
ZA201406400B (en) Eye massage device
EP2841154A4 (en) BLADDER TISSUE MODIFICATION FOR HYPERACTIVE BLADDER TROUBLESHOOTING
EP2895067A4 (en) EVALUATION OF MOBILITY DISORDERS
GB201114212D0 (en) Therapeutic agents
AP2014008011A0 (en) Agents for treating disorders involving modulationof ryanodine receptors
IL228593A0 (en) Treatment of proliferative diseases by a chemoluminescent substance
GB201119401D0 (en) Therapeutic agents
HK1210271A1 (zh) 用於遞送助益劑的眼用裝置
PL2919796T3 (pl) Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
EP2834188A4 (en) FORMATION OF A CONJUGATED PROTEIN BY ELECTROSTATIC WIRING
EP2673363A4 (en) TREATMENT OF ANGIOGENESIS DISORDERS
EP2722041A4 (en) THERAPEUTIC AGENT FOR ALLERGIC RHINITIS
PT2704747T (pt) Colírios para tratamento de conjuntivocálase
GB201118065D0 (en) Treatment of movement disorders
PL395618A1 (pl) Urzadzenie do stabilizacyjnego wzmacniania wlókien miesni
EP2696872A4 (en) TREATMENT OF GLAUCOMA
ES1074678Y (es) Dispositivo de articulacion de un somier
GB201222560D0 (en) Eye massage device
GB201115558D0 (en) Therapeutic agents
GB201110614D0 (en) Therapeutic agents